At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MIRM Mirum Pharmaceuticals, Inc.
Closed 09-29 16:00:00 EDT
87.54
-0.42
-0.48%
盘后88.75
+1.21+1.38%
19:55 EDT
High90.31Low86.51Vol666.83K
Open89.04D1 Closing87.96Amplitude4.32%
Mkt Cap5.68BTradable Cap4.94BTotal Shares64.93M
T/O58.45MT/O Rate1.18%Tradable Shares56.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mirum Pharmaceuticals is Maintained at Buy by Citigroup
Dow Jones  ·  02:06
Mirum Pharmaceuticals is Maintained at Buy by Citigroup
TD Cowen Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
TIPRANKS  ·  09-29 13:25
TD Cowen Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals Price Target Raised to $195.00/Share from $140.00 by HC Wainwright & Co.
Dow Jones  ·  09-29 01:03
Mirum Pharmaceuticals Price Target Raised to $195.00/Share from $140.00 by HC Wainwright & Co.
Mirum's Liver Infection Drug Lowers Virus Levels in Late-Stage Study
Reuters  ·  09-28 23:23
Mirum's Liver Infection Drug Lowers Virus Levels in Late-Stage Study
Mirum Pharmaceuticals, Inc. : Baird Raises Target Price to $130 from $123
THOMSON REUTERS  ·  09-28 21:30
Mirum Pharmaceuticals, Inc. : Baird Raises Target Price to $130 from $123
U.S. Stocks on the MOVE-WhiteHawk, Mirum Pharmaceuticals, Nvidia
Reuters  ·  09-28 20:45
U.S. Stocks on the MOVE-WhiteHawk, Mirum Pharmaceuticals, Nvidia
Mirum Pharmaceuticals, - Phase 3 Primary Endpoint Achieved in Both Dose Arms at Week 24
THOMSON REUTERS  ·  09-28 20:00
Mirum Pharmaceuticals, - Phase 3 Primary Endpoint Achieved in Both Dose Arms at Week 24
Mirum Pharmaceuticals Inc - Favorable Safety and Tolerability Profiles Observed; no New Safety Signals
THOMSON REUTERS  ·  09-28 20:00
Mirum Pharmaceuticals Inc - Favorable Safety and Tolerability Profiles Observed; no New Safety Signals
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 Azure-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
THOMSON REUTERS  ·  09-28 20:00
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 Azure-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals, - Brelovitug Well Tolerated Across Dose Groups with Consistent Safety Profile
THOMSON REUTERS  ·  09-28 20:00
Mirum Pharmaceuticals, - Brelovitug Well Tolerated Across Dose Groups with Consistent Safety Profile
Mirum Rises on FDA Nod for Rare Bone Disorder Drug
Reuters  ·  09-28 18:46
Mirum Rises on FDA Nod for Rare Bone Disorder Drug
Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA
MT Newswires Live  ·  09-28 16:25
Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA
Mirum to Share Phase 3 AZURE-1 Brelovitug Topline Data in Chronic Hepatitis Delta on Sept. 28 Investor Call
Reuters  ·  09-28 05:00
Mirum to Share Phase 3 AZURE-1 Brelovitug Topline Data in Chronic Hepatitis Delta on Sept. 28 Investor Call
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (Zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
THOMSON REUTERS  ·  09-26
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (Zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
US FDA Approves Mirum's Drug for Rare Bone Disorder
Reuters  ·  09-26
US FDA Approves Mirum's Drug for Rare Bone Disorder
Mirum Pharma CMO Rob Myers Files Initial Beneficial Ownership Statement
Reuters  ·  09-23
Mirum Pharma CMO Rob Myers Files Initial Beneficial Ownership Statement
Mirum Grants Inducement Awards to 14 Hires, Including 28,512 Stock Options Priced at USD 100.61 Per Share
Reuters  ·  09-15
Mirum Grants Inducement Awards to 14 Hires, Including 28,512 Stock Options Priced at USD 100.61 Per Share
Mirum Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-15
Mirum Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026
Reuters  ·  09-08
Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026
Mirum Pharmaceuticals Appoints DR. Rob Myers as Chief Medical Officer
THOMSON REUTERS  ·  09-08
Mirum Pharmaceuticals Appoints DR. Rob Myers as Chief Medical Officer

Introduction

Company Name.
Mirum Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Issue price:
--